Marburg I polymorphism of factor VII-activating protease is associated with idiopathic venous thromboembolism

Blood

Volumn 105, Issue 4, 2005, Pages 1549-1551

  Hoppe, Berthold ^a   Tolou, Farzaneh ^a   Radtke, Hartmut ^a   Kiesewetter, Holger ^a   Dörner, Thomas ^a   Salama, Abdulgabar ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 7; ENZYME VARIANT; FACTOR VII ACTIVATING PROTEASE MARBURG 1; PROTEINASE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CAROTID ARTERY OBSTRUCTION; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME POLYMORPHISM; FEMALE; HUMAN; IDIOPATHIC DISEASE; IN VITRO STUDY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; VENOUS THROMBOEMBOLISM;

EID: 13544261410     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-08-3328     Document Type: Article

References (15)

1. Romisch J, Feussner A, Vermohlen S, Stohr HA. A protease isolated from human plasma activating factor VII independent of tissue factor. Blood Coagul Fibrinolysis. 1999;10:471-479.
2. Romisch J, Vermohlen S, Feussner A, Stohr H. The FVII activating protease cleaves single-chain plasminogen activators. Haemostasis. 1999;29:292-299.
3. Roemisch J, Feussner A, Nerlich C, Stoehr HA, Weimer T. The frequent Marburg I polymorphism impairs the pro-urokinase activating potency of the factor VII activating protease (FSAP). Blood Coagul Fibrinolysis. 2002;13:433-441.
4. Willeit J, Kiechl S, Weimer T, et al. Marburg I polymorphism of factor VII-activating protease: a prominent risk predictor of carotid stenosis. Circulation. 2003;107:667-670.
5. Hundsdoerfer P, Vetter B, Stover B, et al. Homozygous and double heterozygous factor V Leiden and factor II G20210A genotypes predispose infants to thromboembolism but are not associated with an increase of foetal loss. Thromb Haemost. 2003;90:628-635.
6. Hoppe B, Heymann GA, Koscielny J, Hellstern P, Kiesewetter H, Salama A. Screening for multiple hereditary hypercoagulability factors using the amplification refractory mutation system. Thromb Res. 2003;111:115-120.
7. Lindmarker P, Schulman S, Sten-Linder M, Wiman B, Egberg N, Johnsson H. The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene, DURAC Trial Study Group: duration of anticoagulation. Thromb Haemost. 1999;81:684-689.
8. Ridker PM, Goldhaber SZ, Danielson E, et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med. 2003;348:1425-1434.
9. Lane DA, Grant PJ. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood. 2000;95:1517-1532.
10. Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med. 1999;340:901-907.
11. Philipp CS, Dilley A, Saidi P, et al. Deletion polymorphism in the angiotensin-converting enzyme gene as a thrombophilic risk factor after hip arthroplasty. Thromb Haemost. 1998;80:869-873.
12. Segui R, Estelles A, Mira Y, et al. PAI-1 promoter 4G/5G genotype as an additional risk factor for venous thrombosis in subjects with genetic thrombophilic defects. Br J Haematol. 2000;111:122-128.
13. Perez-Ceballos E, Corral J, Alberca I, et al. Prothrombin A19911G and G20210A polymorphisms' role in thrombosis. Br J Haematol. 2002;118:610-614.
14. Folsom AR, Cushman M, Tsai MY, et al. A prospective study of venous thromboembolism in relation to factor V Leiden and related factors. Blood. 2002;99:2720-2725.
15. Prandoni P, Bilora F, Marchiori A, et al. An association between atherosclerosis and venous thrombosis. N Engl J Med. 2003;348:1435-1441.